Prediction: Eli Lilly Will Reach $1,200 in 2026
Key takeaways
- LLY NVDA INTC Eli Lilly (NYSE: LLY) doesn t need a perfect year to reach $1,200 in 2026.
- Lilly s GLP-1 franchise, led by Mounjaro and Zepbound, continues to generate extraordinary growth.
- Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need.
LLY NVDA INTC Eli Lilly (NYSE: LLY) doesn t need a perfect year to reach $1,200 in 2026. It does, however, need to maintain its continued dominance in the rapidly growing market for obesity and diabetes drugs -- and that s exactly how things are playing out. Let s see why investors should remain upbeat on Eli Lilly.
Lilly s GLP-1 franchise, led by Mounjaro and Zepbound, continues to generate extraordinary growth. During the first quarter of 2026, Lilly reported nearly $13 billion in combined quarterly revenue from the two drugs. That s not trivial, especially when you consider that the bull case for Lilly increasingly revolves around the future size of the obesity market.
Will AI create the world s first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »